Modality
Gene Editing
MOA
CD47i
Target
APOC3
Pathway
RAS/MAPK
Endometrial CaProstate CaEpilepsy
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
~Nov 2021
→ ~Feb 2023
Phase 2
May 2023
→ Jan 2030
Phase 2Current
NCT04338344
643 pts·Epilepsy
2023-05→2030-01·Active
643 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-283.8y awayPh3 Readout· Epilepsy
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P2/3
Active
Catalysts
Ph3 Readout
2030-01-28 · 3.8y away
Epilepsy
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04338344 | Phase 2/3 | Epilepsy | Active | 643 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |